Bupropion ( DrugBank: Bupropion )

5 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	1
18	Spinocerebellar degeneration	1
21	Mitochondrial disease	1
96	Crohn disease	1
171	Wilson disease	1

8. Huntington disease

Clinical trials : 229 / Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01914965 (ClinicalTrials.gov)	June 2012	31/7/2013	Apathy Cure Through Bupropion in Huntington's Disease	A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease	Apathy;Huntington's Disease	Drug: Bupropion;Drug: Placebo	Charite University, Berlin, Germany	University of Ulm;Ruhr University of Bochum;University Hospital Muenster	Completed	25 Years	75 Years	Both	40	Phase 2	Germany

Clinical trials : 71 / Drugs : 99 - (DrugBank : 30) / Drug target genes : 45 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01716221 (ClinicalTrials.gov)	October 2012	25/10/2012	An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	Friedreich Ataxia	Drug: bupropion & Citalopram;Drug: Bupropion & Placebo;Drug: Placebo & Citalopram;Drug: Placebo & Placebo	University of Colorado, Denver	NULL	Completed	N/A	N/A	Female	1	Phase 4	NULL

Clinical trials : 33 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643249 (ClinicalTrials.gov)	November 10, 2020	13/11/2020	Drug-drug Interaction Study of KL1333 in Healthy Subjects	A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects	Mitochondrial Disease	Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide	Abliva AB	NULL	Completed	18 Years	65 Years	All	14	Phase 1	United Kingdom

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00126373 (ClinicalTrials.gov)	May 2005	2/8/2005	A Trial of Wellbutrin for Crohn's Disease	A Randomized Controlled Trial of Wellbutrin for Crohn's Disease	Crohn Disease	Drug: Wellbutrin (bupropion)	Altschuler, Eric, M.D.	GlaxoSmithKline	Completed	18 Years	N/A	Both	1	Phase 2/Phase 3	United States

Clinical trials : 68 / Drugs : 79 - (DrugBank : 17) / Drug target genes : 3 - Drug target pathways : 28

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04526210 (ClinicalTrials.gov)	October 21, 2020	19/8/2020	Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	A Phase 1, Randomized, 2-Period, 2-Sequence, Cross-over Study to Determine the Effect of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants	Wilson Disease	Drug: ALXN1840;Drug: Bupropion Hydrochloride	Alexion Pharmaceuticals	NULL	Completed	18 Years	50 Years	All	54	Phase 1	United States